ArticleBMC complementary medicine and therapies2025
Efficacy and security of oral Chinese patent medicine combined with antibiotics in the treatment of pelvic inflammatory disease: a Bayesian network meta-analysis.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inducing factors and complication risks of pelvic inflammatory disease: a review.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPelvic inflammatory disease (PID) is a group of female upper genital tract infectious diseases. The efficacy of combining Chinese patent medicine with antibiotics in treating this condition is well-established. Our objective is to conduct a Bayesian network meta-analysis (NMA) to compare the efficacy and security of different oral Chinese patent medicines combined with antibiotics for PID.
methodsRandomized controlled trials (RCTs) reporting oral Chinese patent medicine combined with antibiotics for PID were included by 7 databases from the inception of the databases to December 2024. The Literature that satisfied the inclusion criteria underwent screening, followed by an evaluation of the quality and risk of bias of the studies that were included, in accordance with the Cochrane 5.1 manual and RevMan 5.4. Subsequently, network meta-analysis was conducted using Stata 16.0 and R software.
resultsThere were 73 RCTs included to evaluate the efficacy of 11 Chinese patent medicines combined with antibiotics. Kangfuyan Capsule (KFY) + antibiotics (SUCRA = 87.92%) showed the best efficacy in reducing the VAS (visual analogue scale) score. Jinying Capsule (JY) + antibiotics (SUCRA = 74.29%) showed the shortest time to relieve abdominal pain. Fuyanshu Capsule (FYS) + antibiotics showed the lowest recurrence rate (SUCRA = 99.18%) and were the most effective in reducing the level of C-reactive protein (SUCRA = 93.19%). Fuyankang tablet (FYK) + antibiotics (SUCRA = 91.15%) demonstrated highest security.
conclusionThe efficacy of Chinese patent medicine combined with antibiotics in the treatment of PID is better than that of antibiotics alone. Different Chinese patent medicines have their own advantages in improving abdominal pain symptoms, reducing recurrence rate and inflammatory factors levels. Clinically, these drugs can be objectively selected based on the results of the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.